January 26, 2017 6:46pm
Lately, sector performance is just a matter of timing and the usual catch-up of advance/decline lines and alternating daily closes
While short interest ratios ramble some for and much against the “usual suspects”
Pre-open indication’s tally: 3 hit (KITE, ONCE and OSIR) and 2 miss (BSTG and CLBS)
Out and about: Athersys (ATHX) intends a public offering
I answer one question; in which company should investors put, keep and commit their money!
… As I focus on the facts in evidence …
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. equities closed mixed on Thursday after hitting new record highs, as investors digested several key earnings reports.
The NASDAQ closed DOWN -1.16 or -0.02% to 5655.18 and the DOW closed UP +32.40 or +0.16% to 20,100.91.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 24/15 and 4 flats;
- The mid-day stayed negative with an A/DL of 18/24 and 1 flat;
- The close stayed negative with an A/DL of 14/24 and 5 flats;
Henry’omics:
From the mid-day’s investor’s letter, “Investor are about to reach the beginning of the Q4 financial results season, notice I did NOT say earnings period.
- As I had stated, “The deluge of releases in the next two weeks will confirm whether the final three months of 2016 that marked a share pricing decline and increased spending and the biggest issue – LOW cash balances …”
Will be the hurdle that complexes the difficulty for managements to define their focus for the New Year and provide guidance and a forecast of ANY corporate ambition.
- Companies need to POSITION themselves … AWAY and DIFFERENTIATE their cell and regenerative therapy platforms!
And focus on plausible and eventually… unsustainable price targets that actually might be … MET!
By the way, do you know why some companies are rushing=out any iteration of a financing – they’re … BROKE … beyond Q1/17
Indexes, the ebb and flow:
- The iShares Russell 2000 (IWM) indicated a positive +0.09% in the pre- open and closed DOWN -0.40%.
- The iShares NASDAQ Biotechnology (IBB) indicated a positive +0.10% in the pre-open and closed DOWN -0.36%
Pre-open indication’s tally: 2 hit (ONCE and OSIR) and 3 miss (BSTG, CLBS and KITE)
- Biostage (BSTG) closed UP +$0.04 – miss;
- Caladrius Biosciences (CLBS) closed UP +$0.085 – miss;
- Kite Pharma (KITE) closed DOWN -$0.01 – hit;
- Osiris (OSIR) closed DOWN -$0.13 – hit;
- Spark Therapeutics (ONCE) DOWN -$0.53 – hit;
Out and about:
Athersys (ATHX) proposes offering
- No share amounts or pricing as the stock closes FLAT at $1.52, watch for the discount spiral - SELL
- ATHX intends to offer for sale shares of its common stock in an underwritten public offering pursuant which will be sold by William Blair & Company, L.L.C. acting as sole book-running manager and Needham & Company, LLC is acting as lead manager for the offering.
Today’s 5 top dollar gainers included:
- bluebird bio (BLUE) -+$0.65;
- Caladrius Biosciences (CLBS) +$0.11;
- Brainstorm (BCLI) +$0.08;
- Cesca Therapeutics (KOOL) +$0.06
- uniQure (QURE) +$0.05
Today’s 5 largest dollar losers of the session were:
- Spark Therapeutics (ONCE) -$0.53 after Wednesday’s +$0.76 after Monday’s +$0.39 after Friday’s +$1.23;
- Cellectis SA (CLLS) -$0.50;
- Stemline (STML) -$0.45 after Wednesday’s +$0.25;
- Intrexon (XON) -$0.36 after Wednesday’s -$0.51 after Tuesday’s -$0.44 after Monday’s -$1.22;
- Bellicum (BLCM) -$0.32 after Wednesday’s +$0.32
Flat:
- Adverum (ADVM) at $2.90;
- Athersys (ATHX) at $1.52;
- Cytori (CYTX) at $1.56
- Histogenics (HGX) at $1.54;
- ReNeuron (RENE.L) at $2.625
The downside trend reflects a pricing trend range of:
- Thursday’s decliners ranged from -0.02% <KITE> to -6.45% <AST> in 24 equities;
- Wednesday’s decliners ranged from -0.30% <BTX> to -7.444% <IMUC> in 12 equities;
- Tuesday’s decliners ranged from -0.44% <CAPR> to -3.57% <AGTC> in 15 equities;
- Monday’s decliners ranged from -0.08% <BLUE> to -10.46% <FATE> in 25 equities;
- Friday’s decliners ranged from -0.25% <MDXG> to -17.86% <PSTI> in 26 equities;
- Last Thursday’s decliners ranged from -0.20% <OSIR> to -6.71% <HSGX> in 32 equities;
The upside shows a pricing trend range of:
- Thursday’s gainers ranged from +0.17% <MESO> to +4.95% <NWBO> in 14 equities;
- Wednesday’s gainers ranged from +0.22% <ONCE> to +10.49% <FCSC> in 28 equities;
- Tuesday’s gainers ranged from +0.35% <KOOL> to +14.78% <IMUC> in 26 equities;
- Monday’s gainers ranged from +0.55% <ONCE> to +5.07% <KOOL> in 13 equities;
- Friday’s gainers ranged from +0.31% <CAPR> to +14% <ISCO> in 15 equities;
- Last Thursday’s gainers ranged from +0.11% <KITE> to +8.68% <ISCO> in 8 equities;
The week’s beginning:
- Thursday’s 14 gainers followed Wednesday’s 28, Tuesday’s 26, Monday’s 13, Friday’s 15 and last Thursday’s 8
- Thursday’s 24 decliners followed Wednesday’s 12, Tuesday’s 15, Monday’s 25, Friday’s 26 and last Thursday’s 32
Review my fear gauge or the CBOE Volatility Index (VIX):
· Thursday traded near 10.9;
· Wednesday traded near 10.8;
· Tuesday traded near 11.4;
· Monday traded near 12.2;
· Friday traded near 12.3;
· Last Thursday traded near 12.4;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
